Ismailov Zaurbek, Rasa Agnija, Bandere Katrīna, Brokāne Linda, Tilgase Andra, Olmane Evija, Nazarovs Jurijs, Alberts Pēteris
Private Practice, Grozny, Chechnya, Russian Federation.
International Virotherapy Center, Research and Development, Riga, Latvia.
Am J Case Rep. 2019 Jan 12;20:48-52. doi: 10.12659/AJCR.912115.
BACKGROUND Renal cell carcinoma is the most commonly diagnosed primary malignant tumor of the kidney in adults, and includes the variant of chromophobe renal cell carcinoma. Despite new targeted therapies that improve progression-free survival (PFS) and overall survival (OS) for early-stage renal cell carcinoma, the 5-year survival for patients with stage IV renal cell carcinoma remains below 10%, and the 50% OS is less than one year. Metastatic renal cell carcinoma can be resistant to cytotoxic chemotherapy. This report is of a case of stage IV chromophobe renal cell carcinoma that responded well to treatment with the oncolytic ECHO-7 virus, Rigvir®. CASE REPORT In December 2015, a 59-year-old man presented with a right-sided chromophobe renal cell carcinoma stage IV (pT₁N₀M₁) with adrenal gland metastasis. He underwent right nephro-adrenalectomy followed by treatments with Rigvir® (≥10⁶ TCID₅₀/ml) by intramuscular (i.m.) injection on three consecutive days. Treatment with Rigvir® continued once per week for three months, and from March 2016, once per month, with continued treatment until computed tomography (CT) scans confirmed that the tumor metastases had stabilized. CONCLUSIONS This case report has demonstrated that the oncolytic ECHO-7 virus, Rigvir® should be evaluated further as a potential treatment for advanced renal carcinoma.
背景 肾细胞癌是成人中最常被诊断出的原发性肾脏恶性肿瘤，包括嫌色肾细胞癌变体。尽管新的靶向治疗改善了早期肾细胞癌的无进展生存期（PFS）和总生存期（OS），但IV期肾细胞癌患者的5年生存率仍低于10%，且50%的总生存期不足一年。转移性肾细胞癌可能对细胞毒性化疗耐药。本报告介绍了一例IV期嫌色肾细胞癌患者，其对溶瘤性ECHO-7病毒Rigvir®治疗反应良好。病例报告 2015年12月，一名59岁男性被诊断为IV期（pT₁N₀M₁）右侧嫌色肾细胞癌伴肾上腺转移。他接受了右肾肾上腺切除术，随后连续三天通过肌肉注射给予Rigvir®（≥10⁶ TCID₅₀/ml）治疗。Rigvir®治疗持续了三个月，每周一次，从2016年3月起改为每月一次，持续治疗直至计算机断层扫描（CT）证实肿瘤转移已稳定。结论 本病例报告表明，溶瘤性ECHO-7病毒Rigvir®作为晚期肾癌的潜在治疗方法应进一步评估。
